Company intelligence / Profile preview

Immuneel Therapeutics

Bengaluru, Karnataka, Indiaimmuneel.com ↗

Ownership: Private
Employees: ~47
Development stage: Phase 2

Overview

Immuneel's flagship product Qartemi (varnimcabtagene autoleucel - IMN-003A) has shown potential to provide lasting remission of relapsed and refractory NHL, even when conventional therapies including chemotherapy prove ineffective. Clinical trials in India and Spain show safety and efficacy similar to FDA-approved CAR-T therapies, at one-tenth the cost of similar products in the US[6].

Therapeutic areas: OncologyHematology
Modalities: Cell and gene therapiesCAR-T cell therapy
Industry: Biotech

Drug pipeline

4 assets

IMN-005

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Hospital Clinic de Barcelona (HCB)Institut d'Investigacions Biomèdiques August Pi i Sunyer

Beyond the preview

Go deeper on Immuneel Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immuneel Therapeutics.

Explore the full profile